[go: up one dir, main page]

AR073435A1 - Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine - Google Patents

Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine

Info

Publication number
AR073435A1
AR073435A1 ARP070104457A ARP070104457A AR073435A1 AR 073435 A1 AR073435 A1 AR 073435A1 AR P070104457 A ARP070104457 A AR P070104457A AR P070104457 A ARP070104457 A AR P070104457A AR 073435 A1 AR073435 A1 AR 073435A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
modified release
nsaid
combination
relaxing muscle
Prior art date
Application number
ARP070104457A
Other languages
English (en)
Inventor
Hernandez Gustavo Barranco
Paniagua Angelica Arzola
Lopez Enrique Raul Garcia-Salgado
Lopez Luis Fernando Poot
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of AR073435A1 publication Critical patent/AR073435A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composicion farmacéutica de liberacion modificada en cápsulas con microesferas recubiertas que comprende la combinacion de dos principios activos de tiempos de concentracion plasmática radicalmente diferentes, éstos son un musculo relajante(tizanidina) y un analgésico antiinflamatorio no esteroide (meloxicarn), vehículos o excipientes farmacéuticamente aceptables; así como a un proceso para la manufactura de la composicion y al uso de dicha combinacion para la preparacion de unmedicamento con actividad terapéutica sinérgica indicada en el tratamiento de espasticidad, desordenes relacionados con padecimientos musculares y/o musculo esquelético y dolor en general de moderado o severo.
ARP070104457A 2006-10-18 2007-10-09 Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine AR073435A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA06012024 2006-10-18

Publications (1)

Publication Number Publication Date
AR073435A1 true AR073435A1 (es) 2010-11-10

Family

ID=39313650

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104457A AR073435A1 (es) 2006-10-18 2007-10-09 Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine

Country Status (16)

Country Link
US (1) US20100166856A1 (es)
EP (1) EP2085076B1 (es)
AR (1) AR073435A1 (es)
AT (1) ATE499089T1 (es)
BR (1) BRPI0718368A2 (es)
CA (1) CA2670690C (es)
CL (1) CL2007002975A1 (es)
CO (1) CO6140021A2 (es)
CR (1) CR10801A (es)
DE (1) DE602007012751D1 (es)
EC (1) ECSP099348A (es)
ES (1) ES2361883T3 (es)
GT (1) GT200900089A (es)
PE (1) PE20081464A1 (es)
UY (1) UY30636A1 (es)
WO (1) WO2008047208A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2381937A2 (en) 2008-12-31 2011-11-02 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
AU2009352681B2 (en) * 2009-09-17 2014-11-20 Upsher-Smith Laboratories, Llc A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
ES2596359T3 (es) 2009-12-18 2017-01-09 Mdm S.P.A. Formas de dosificación farmacéuticas de tizanidina y su vía de administración
BRPI1103205A2 (pt) * 2011-06-03 2014-02-25 Eurofarma Lab Ltda Composição farmacêutica oral e uso da composição farmacêutica oral
AU2013252491A1 (en) * 2012-04-27 2014-11-06 Troy Laboratories Pty Ltd Combination meloxicam and xylazine therapy in animals
EA201692426A1 (ru) * 2014-07-21 2017-05-31 Сановель Илач Санайи Ве Тиджарет А.Ш. Комбинации зальтопрофена и миорелаксанта
WO2016193880A1 (en) * 2015-05-29 2016-12-08 Jubilant Generics Limited Immediate release pharmaceutical composition of tizanidine
US20190060287A1 (en) * 2017-08-28 2019-02-28 Adare Pharmaceuticals, Inc. Tizanidine formulations
EP4331588A4 (en) * 2021-04-27 2025-01-15 Animuscure Inc. COMPOSITION FOR THE PREVENTION OR TREATMENT OF MUSCLE DISEASES WITH AN OXICAM-BASED COMPOUND
CN113398096A (zh) * 2021-06-27 2021-09-17 烟台大学 一种含有美洛昔康的长效注射微球及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735369B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
KR100210509B1 (ko) * 1996-01-10 1999-07-15 성재갑 지속성 동물 성장 호르몬 제형 및 이의 제조 방법
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
US20040204413A1 (en) * 2001-01-26 2004-10-14 Joaquina Faour Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant
CA2403670C (en) * 2001-01-31 2010-02-09 Rohm Gmbh & Co. Kg Multiparticulate drug form comprising at least two differently coated pellet forms
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
US8502335B2 (en) 2009-07-29 2013-08-06 Taiwan Semiconductor Manufacturing Company, Ltd. CMOS image sensor big via bonding pad application for AlCu Process

Also Published As

Publication number Publication date
BRPI0718368A2 (pt) 2013-11-12
DE602007012751D1 (de) 2011-04-07
PE20081464A1 (es) 2008-12-31
CA2670690C (en) 2014-12-30
ATE499089T1 (de) 2011-03-15
ECSP099348A (es) 2009-06-30
ES2361883T3 (es) 2011-06-24
WO2008047208A1 (es) 2008-04-24
EP2085076A4 (en) 2010-03-17
CA2670690A1 (en) 2008-04-24
US20100166856A1 (en) 2010-07-01
CO6140021A2 (es) 2010-03-19
GT200900089A (es) 2012-01-13
EP2085076B1 (en) 2011-02-23
EP2085076A1 (en) 2009-08-05
CL2007002975A1 (es) 2008-01-04
UY30636A1 (es) 2008-05-02
CR10801A (es) 2009-07-03

Similar Documents

Publication Publication Date Title
AR073435A1 (es) Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine
Kulkarni et al. On the mechanism of antidepressant-like action of berberine chloride
Cánovas et al. Dopaminergic agonists in Parkinson's disease
EP4631571A3 (en) Combination of dextromethorphan and bupropion for treating depression
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
Gordi et al. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive-extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects
EP2444072A3 (en) Non-mucoadhesive film dosage forms
Tuite et al. Recent developments in the pharmacological treatment of Parkinson’s disease
WO2006069293A3 (en) Composition comprising n-acetylcysteine and further pain or anti- inflamm medications
Bastos et al. Drug repositioning: playing dirty to kill pain
ATE494889T1 (de) Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
BRPI0512311A (pt) uso de meloxicam em medicina veterinária para o tratamento de doenças inflamatórias dolorosas
AR056824A1 (es) Tableta de neramexano con matriz de liberacion modificada
RU2014129508A (ru) Новая комбинация
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
Zhu et al. Tizanidine: advances in pharmacology & therapeutics and drug formulations
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
JP2016505050A5 (es)
CN105209044B (zh) 用于疼痛病症的治疗性米氮平组合物
Oldfield et al. Oxycodone/Ibuprofen combination tablet: a review of its use in the management of acute pain
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
RU2012129839A (ru) Комбинация теобромина с деконгестантом и ее применение для лечения кашля

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure